Who owns X4 PHARMACEUTICALS INC COM NEW?
- Ticker: XFOR
- CUSIP Number: 98420x202
Tip: Access positions for across all investors
Analyze quarterly positions in X4 Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of X4 Pharmaceuticals stock
Who bought or sold X4 PHARMACEUTICALS INC COM NEW this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors | 2.4M | $8.3M | 332% | Sep 2025 |
|
| BVF | 2.2M | $7.6M | 100% | Sep 2025 |
|
| Nantahala Capital Management | 2.2M | $7.6M | 100% | Sep 2025 |
|
| Rosalind Advisors | 1.5M | $5.3M | 100% | Sep 2025 |
|
| Deep Track Capital | 1.1M | $3.8M | 100% | Sep 2025 |
|
| Stonepine Capital Management | 1.1M | $3.6M | 100% | Sep 2025 |
|
| Kingdon Capital Management | 933k | $3.2M | 300% | Sep 2025 |
|
| Stempoint Capital | 555k | $1.9M | 100% | Sep 2025 |
|
| Vanguard Group | 411k | $1.4M | 77% | Sep 2025 |
|
| Boothbay Fund Management | 344k | $1.2M | 100% | Sep 2025 |
|
| Pale Fire Capital SE | 181k | $619k | 201% | Sep 2025 |
|
| UBS Group | 160k | $544k | 45% | Sep 2025 |
|
| Susquehanna International | 128k | $437k | -21% | Sep 2025 |
|
| Palumbo Wealth Management | 95k | $326k | 100% | Sep 2025 |
|
| Geode Capital Management | 80k | $273k | 62% | Sep 2025 |
|
| Millennium Management | 65k | $222k | -17% | Sep 2025 |
|
| BlackRock | 62k | $212k | -65% | Sep 2025 |
|
| State Street Corporation | 39k | $133k | 149% | Sep 2025 |
|
| Point72 Asset Management | 22k | $74k | 0% | Sep 2025 |
|
| Renaissance Technologies | 19k | $66k | 10% | Sep 2025 |
|
| Two Sigma Investments | 14k | $47k | 100% | Sep 2025 |
|
| Morgan Stanley | 11k | $21k | 100% | Jun 2025 |
|
| Tower Research Capital | 11k | $37k | 105% | Sep 2025 |
|
| Group One Trading | 4.0k | $14k | 0% | Sep 2025 |
|
| Point72 Asia | 2.9k | $10k | 100% | Sep 2025 |
|
| Royal Bank of Canada | 2.5k | $15k | -18% | Sep 2025 |
|
| Atlantic Trust | 2.2k | $7.4k | 0% | Sep 2025 |
|
| Pnc Financial Services | 1.8k | $6.0k | -2% | Sep 2025 |
|
| TD Waterhouse Canada | 1.5k | $5.4k | 0% | Sep 2025 |
|
| Russell Investments | 729.00 | $2.5k | -93% | Sep 2025 |
|
| Bleichroeder | 595.00 | $2.0k | 0% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 554.00 | $1.9k | -13% | Sep 2025 |
|
| Ronald Blue Trust | 284.00 | $970.996000 | 0% | Sep 2025 |
|
| SBI Securities | 216.00 | $739.000800 | 0% | Sep 2025 |
|
| Jones Financial Companies, L.L | 38.00 | $131.001200 | 0% | Sep 2025 |
|
| Rockefeller Capital Management | 33.00 | $112.998600 | 100% | Sep 2025 |
|
| Jpmorgan Chase & Co | 33.00 | $112.998600 | 100% | Sep 2025 |
|
| Goss Wealth Management | 33.00 | $112.998600 | 0% | Sep 2025 |
|
| HighMark Wealth Management | 6.00 | $21.000000 | 0% | Sep 2025 |
|
Who sold out of X4 Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| GSA Capital Partners | Jun 2025 | 133k | $252k |
| Jane Street | Jun 2025 | 97k | $185k |
| UBS O'Connor | Jun 2025 | 80k | $152k |
| Squarepoint Ops | Jun 2025 | 39k | $74k |
| AQR Capital Management | Jun 2025 | 26k | $50k |
| Virtu Financial | Jun 2025 | 13k | $24k |
| Schonfeld Strategic Advisors | Jun 2025 | 11k | $21k |
| Hrt Financial | Jun 2025 | 11k | $20k |
| CWM | Jun 2025 | 2.4k | $5.0k |
| FMR | Jun 2025 | 1.7k | $3.2k |
| SRS Capital Advisors | Jun 2025 | 1.1k | $2.1k |
| Wells Fargo & Company | Jun 2025 | 348.00 | $660.991200 |
| Federated Investors | Jun 2025 | 149.00 | $282.995700 |
| NISA Investment Advisors | Jun 2025 | 139.00 | $264.002700 |
| Raymond James Financial | Jun 2025 | 66.00 | $124.997400 |
| Hartland & Co | Jun 2025 | 64.00 | $121.996800 |
| EverSource Wealth Advisors | Jun 2025 | 23.00 | $43.999000 |